NCT02849249View on ClinicalTrials.gov

A Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Olea Europaea and Phleum Pratense

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Rhinoconjuntivitis
Interventions
BIOLOGICAL

allergovac polimerized (100/100)

Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.

Trial Locations (5)

18012

Hospital Clínico Granada, Granada

41009

Hospital Virgen Macarena, Seville

41013

Hospital Universitario Virgen del Rocío, Seville

06300

Hospital de Zafra, Zafra

Unknown

Hospital de Henares, Henares

All Listed Sponsors
lead

Roxall Medicina España S.A

INDUSTRY

NCT02849249 - A Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Olea Europaea and Phleum Pratense | Biotech Hunter | Biotech Hunter